Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Inmagene Approved to Start US Trials of HutchMed Immune Disease Therapy

publication date: May 2, 2022

Shanghai Inmagene Biopharmaceuticals was approved to start US trials of an OX40 mAb that targets immune diseases including atopic dermatitis. Inmagene is developing IMG-007 in partnership with HutchMed and has an exclusive option to in-license the candidate. In 2021, Inmagene in-licensed global rights to four novel pre-clinical immunological candidates from HutchMed in a $920 million deal. The two companies partner pre-clinical development, while Inmagene is responsible for global clinical trials. IMG-007 is designed to inhibit binding of OX40 to OX40L reducing T cell release. More details....

Stock Symbols: (NSDQ/AIM: HCM; HK:13)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital